CANCER AND AUTOIMMUNE DISEASES
We are armed
to fight!
NEWS & EVENTS
Headlines
Boehringer Ingelheim and OSE Immunotherapeutics
To Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
A clinical-stage biotechnology company in immunotherapy
focused on developing and partnering therapies to control the immune system
for immuno-oncology and autoimmmune diseases.
5
Products in clinical-stage status
3
Partnerships with international pharma companies
70
High-level collaborators
OSE Immunotherapeutics,
a clinical-stage biotechnology company
focused on developing and partnering therapies to control the immune system
for immuno-oncology and autoimmmune diseases.
Collaborations and partnerships
A fundamental element of both long-term strategy and day-to-day operations
-
Scientific and Technological
Platforms
Neoepitopes,
agonist or antagonist monoclonal antibodies
+
-
Immuno-oncology
T-cell activation through neoepitopes
Transforming tumor microenvironment
suppressive cells into effector cells
+
-
Autoimmune Diseases
Down regulating T effector cells to decrease immunological reactivity
Up regulating regulatory
T-cells to develop immune tolerance
+
-
Partnerships
Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need
+
Boehringer Ingelheim and OSE Immunotherapeutics…
DISCOVER
+
Boehringer Ingelheim and OSE Immunotherapeutics…
DISCOVER
+
OSE Immunotherapeutics Receives U.S. Patent…
DISCOVER
+
To receive OSE Immunotherapeutics’ latest news
